news

  • 18 May 2016
    Wilson Therapeutics announces that the ongoing Phase II study has been fully enrolled

    Wilson Therapeutics AB (publ), announces that the company's ongoing Phase II clinical trial evaluating the safety and efficacy of Decuprate® (bis-choline tetrathiomolybdate; WTX101) in Wilson Disease patients has been fully enrolled.

     

    Read the full press release at

    https://www.wilsontherapeutics.com/en/wilson-therapeutics-announces-that-the-ongoing-phase-ii-study-has-been-fully-enrolled/

     

    About Wilson Therapeutics

    Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases such as Wilson Disease. Wilson Therapeutics’ lead product, Decuprate®, is initially being developed as a novel treatment for Wilson Disease and is currently being evaluated in a Phase II clinical study in Wilson Disease patients. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.

    Visit www.wilsontherapeutics.com for more information.

     

    For more information contact

    Jonas Hansson, CEO, Wilson Therapeutics AB

    Tel: +46 8 796 00 00

    Email:

     

    Wilson Therapeutics AB (publ)

    Org nr 556893-0357

    Västra Trädgårdsgatan 15

    SE-111 53 Stockholm